Press coverage about Strongbridge Biopharma (NASDAQ:SBBP) has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Strongbridge Biopharma earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.5515267700326 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

Strongbridge Biopharma (NASDAQ:SBBP) opened at $8.45 on Tuesday. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma has a 1 year low of $2.10 and a 1 year high of $8.85. The firm has a market cap of $336.41 and a P/E ratio of -2.50.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.07. analysts expect that Strongbridge Biopharma will post -2.86 earnings per share for the current fiscal year.

Several research firms recently weighed in on SBBP. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. Zacks Investment Research cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. BidaskClub upgraded shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Cantor Fitzgerald set a $14.00 price objective on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, ValuEngine cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $12.81.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Strongbridge Biopharma (SBBP) Share Price” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-strongbridge-biopharma-sbbp-share-price/1819609.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Insider Buying and Selling by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.